09:02 AM EST, 12/11/2024 (MT Newswires) -- Alpha Cognition ( ACOG ) on Wednesday said interim preclinical data support the development of its lead candidate ALPH-1062 for the treatment of mild traumatic brain injury (mTBI) resulting from repetitive blast trauma, a signature injury affecting soldiers.

Key findings showed that high dose ALPHA-1062 reduced the levels of myeloid cell activation across multiple brain regions one month after blast. High dose ALPHA-1062 also showed an ability to reduce midbrain astrogliosis, a condition where brain cells called astrocytes become larger, multiply, and change in response to injury or disease in the brain.

"These outcomes indicate a protective effect of ALPHA-1062, and demonstrated a reduction of neuropathology. The data provide further support for the continued development of ALPHA-1062 for the treatment of acute mild traumatic brain injury," said Denis Kay, Chief Scientific Officer.